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Activation of antigen-specific helper/inducer T cells requires that antigen be
presented by APC in association with selfMHC class II molecules (1). Recent evi-
dence indicates that APC accomplish this by degrading exogenous soluble proteins
to peptide fragments, which become bound to class II molecules (2, 3). The amino
acid residues ofhuman class II molecules thatinteract with immunogenic peptides,
with the TCR or with accessory molecules such as CD4, are for the most part un-
known. As an approach tomapping such residues, we arestudyingstructure-function
relationships in immunoselected mutant B lymphoblastoid cell lines (B-LCLs), that
express altered HLA-DR3 molecules. B-LCLs present soluble antigens to antigen-
specific, HLA class II-restricted T cells (4), making it possible to assay the func-
tional effects ofmutational alterations in class II molecules. Mutational analysis has
proved useful for mapping serologic epitopes and T cell restriction sites on human
class I molecules (5) and murine class I and II molecules (5, 6). However, single
amino acid substitutions that affect antigen presentation in human cells have not
previously been reported.
To generate class II mutants in a human APC line, we mutagenized an HLA-
DR3-expressing B-LCL with ethyl methane sulfonate. To simplify the analysis, we
used as the progenitor line 8 .1.6, a deletion mutant that lacks all DR and DQ genes
of one haplotype, but expresses the class II loci of the other haplotype, DR3, nor-
mally (referred to in reference 6a). Immunoselection of mutagenized 8.1.6 with an
anti-DR3-specific mAb, 16.23, yielded several types of mutants (7). Here, we de-
scribe one immunoselected mutant, 7 .13.6, that expresses a structurally altered DR3
molecule and has a selective loss in DR3-restricted antigen presentation compared
with its progenitor, 8.1.6. The mutation 7 .13.6 maps to the first hypervariable region
of the DR3 R chain.
Materials and Methods
APCLines.
￿
With the exception ofmutant clones 7.13.6 and 7.25 .6, the B-LCLs have been
reported. 8.1.6 is derived from T5-1 progenitor line (7); 9.22.3 is a homozygous DRa dele-
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tion mutant derived from 8 .1.6 (6a) ; 9.4.3 is an 8 .1.6-derived mutant that lacks DR01 mRNA
(7) ; 6 .1 .6 is a class II-negative regulatory mutant derived from T5-1 (7) . 7.13.6 and 7 .25.6
are DR3 mutants isolated by a described protocol (7) . Mutant 7.25.6 expresses a DRSI chain
with a more acidic isoelectric point (pl) than that of 8 .1.6 (not shown) . 7.25.6 binds 45 t
4% of 8 .1.6 levels of anti-DR mAb VI .15, 35 t 4% of anti-DR3 mAb 16.23, and 48 t 6%
of anti-DR3 mAb CD6B1 .
Two-dimensional Gel Analysis.
￿
31S-labeled DR molecules were immunoprecipitated with
anti-DR mAb VI.15 (7) . Immunoprecipitates, with or without prior digestion with Endo
F, were subjected to electrophoresis on two-dimensional (2-D) gels, as described (Cotner, T.,
submitted for publication) .
Radioimmune Binding Assays.
￿
For binding assays, mAbs 16.23, anti-DR3 specific (8) ; CD6B1,
anti-DR3 specific (9) ; 7.3.19, anti-DRw52 specific (10) ;VI.15, anti-DR monomorphic (7) were
used . Cells were assayed with saturating amounts of mAb and 1251 protein A or 1251-rat
anti-mouse x chain as a second reagent, as described (7) .
T Cell Proliferation Assays.
￿
Human T cell lines specific for soluble protein antigen were
generated as described (4) . Antigens tetanus toxoid (TT), PPD, and Candida albicans extract
were used as described (4); recombinant hepatitis B surface antigen (HBsAg), the generous
gift ofMerck Sharp & Dohme (West Point, PA) was used at 10 ug/ml . T cell clones (ND-
PPD1, ND-PPD2, CT-TT, BJ-HBsAg) are designated by donor-antigen and were obtained
by limiting dilution cloning in the presence of antigen, exogenous IL-2, and irradiatedPBMC
as APC . ND-PPD, and ND-PPD2 are PPD-specific clones with different reactivity patterns ;
they are likely to recognize different peptides derived from PPD, which is a mixture of pro-
teins. 1 .5 x 104 T cell blasts were cocultured with 105 mitomycin C-treated B-LCLs as APC
in the presence or absence of soluble antigen ; stimulation was measured by the incorporation
of [3H]thymidine into DNA, as described (4) .
Polymerase Chain Reaction (PCR) Amplification and Sequence Analysis.
￿
cDNAs prepared from
poly(A)' RNA from 8 .1.6 and 7 .13.6 were size selected (>0.7 kb) on an agarose gel and sub-
jected to PCR amplification using Taq I polymerase (11) . DRa primers were selected based
on published sequences (12) . DRa primers were selected based on the sequence of a DR301
cDNA clone from 8 .1 .6 (B . Arp, unpublished results) . All primer sequences are available on
request . Size-selected double-stranded PCR DNA was subjected to dideoxy sequencing using
modified T7 DNA polymerase (Sequenase, U.S. Biochemical Corp ., Cleveland, OH) . The
PCR primers and additional oligonucleotide primers covering 21 by segments of the coding
regions were used to generate overlapping 100-250 base segments of sequence information .
Results and Discussion
We initially analyzedDR molecules from mutant 7 .13.6 and its progenitor 8 .1.6,
by 2-D SDS-PAGE electrophoresis (Fig . 1) . 8 .1.6, like other cells bearing the DR3
haplotype, expresses a single DRa chain and two DRa chains, at and a1II, each of
which forms a heterodimer with DRa . Comparison of the 7 .13.6 and 8 .1.6 2-D gel
patterns reveals that mutant 7.13 .6 expresses an altered DRDI chain, whose pI is two
charges more basic than that of 8 .1.6 (see Fig . 1, legend).
To evaluate the level of cell surface expression of the mutant DR3 molecule ex-
pressed by 7.13 .6, we compared cell surface binding with 7.13 .6 and 8.1.6 by a panel
of four mAbs that bind to DR3 molecules (Table I) . On the basis of their different
fine specificities (see Materials and Methods) and inability to crossinhibit each other
(not shown), these antibodies are likely to react with distinct epitopeson DR3 mole-
cules . At antibody concentrations that are saturating for 8 .1.6, the binding of each
antibody to 7.13.6 is moderately reduced (40-70%) from 8.1.6 levels . For both the
DR3-specific mAb 16.23 and the monomorphic anti-DR mAb VI .15, binding to
7 .13.6 saturates at 50 17o of the concentration required to saturate 8 .1.6 (not shown) .
These data suggest that the mutant molecules in 7 .13 .6 are expressed in decreasedMELLINS ET AL .
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FIGURE 1 .
￿
(A) 2-D SDS-PAGE analysis ofEndo F-treated HLA-DR moleculesfrom parent line
8.1.6 and mutant 7.13.6. The designations of 8.1.6 0 chains as DI and pill are based on compar-
isons of limited NH2-terminal amino acid sequencing with the published DR3p1 and 9111 gene
sequences (14 andT Cotner, unpublished results) . In both 7.13.6 and 8.1.6 gels, the 01 spot is
more abundant than the pill spot; the pt spots are also marked by a weaker spot of the same
pI but lower molecular weight, which most likely represents a proteolytic breakdown product .
In the 8.1.6 gel, the DI spot obscures the more basic pill spot. To compare the 7 .13.6 and 8.1 .6
patterns, the p chain spots are aligned by the pill spots, which cofocus in the 8.1.6/7.13 .6 mix-
ture . The different positions oftheDRa spots in the different gels are due to differential stretching
of the gels . However, the8.1.6/7.13 .6 mixture, being internally controlled for stretching, demon-
strates that the DRa species from 7.13.6 cofocuses with that of 8.1.6, whereas the 7 .13.6 p1 chain
is more basic than that of8.1 .6 . p, parental ; m, mutant. (B)2-D SDS-PAGE analysis ofnon-Endo
F-treated HLA-DR molecules from 8.1 .6 and 7.13.6. The pt chain pattern from 8.1 .6 includes
the prominent, nonsialated pI spot and amore acidic glycosylation ladder consisting of three
spots of increasing acidity. A fifth spot, the nonsialated pill chain, is visualized to the basic side
of the pl spot ; its glycosylation ladder is obscured by the pl spots. In 7 .13.6, the nonsialated p1
chain and its glycosylation ladder are shifted to the basic side (relative to 8.1.6) and overlap the
pill spots . In the8.1.6/7.13 .6mixture the nonsialated pi chain of 7.13.6 anda single glycosylation
intermediate are visualized on the basic side ofthe nonsialated 8.1 .6 p1 chain . Because each sialy-
ation contributes 1 acidic charge, this pattern suggests that the 7.13.6 p1 chain has undergone
a 2 charge basic shift in pl compared with 8.1 .6 .
amounts on the cell surface, possibly because the mutant RI chains associate less
efficiently than 8.1.6 at chains with the DRa chain.
To evaluate DR3-restricted antigen presentation in 7 .13 .6, we tested the ability
of 7.13 .6 to stimulate proliferation of antigen-specific DR301-restricted T cells de-
rived from normal DR3 donors . DR30rrestrictedT cells were identified as cells that
respond to antigen presentation by 8.1 .6 but not by an 8.1.6-derived mutant that
has lost DROI expression (mutant 9.4.3) . As shown on Table II, mutant 7.13 .6 is
unable to stimulate ND-PPDI, a DR301-restricted T cell clone specific for PPD.
However, the mutant DR3 molecules of 7.13 .6 function as effectively as those of 8.1.6
in stimulating a DR301-restricted TTspecific clone CT-TT, a second DR3Q1-
restricted PPD-specific clone, ND-PPD2, and DR3S1-restricted T cells specific for1534 AN AMINO ACID SUBSTITUTION ALTERS ANTIGEN PRESENTATION
TABLE I
Cell Surface Radioimmune Binding Analysis ofMutant 7.13.6 and
8.1.6 with a Panel ofAnti-DR Antibodies
Antibody
Cell line
￿
16.23
￿
CD6B1
￿
7.3 .19
￿
VI. 15
8.1 .6
￿
100*
￿
100
￿
100
￿
100
7.13.6
￿
29 t4
￿
45 t4
￿
66 t2
￿
47 t6
* Binding ratio is calculated as (cpm bound by mutant - cpm bound by nega-
tive control)/(cpm bound by 8.1 .6 - cpm bound by negative control). Data
represent medians t SEM from four or more experiments. Negative control
was the DR null mutant, 9.22 .3. cpm bound by 9.22.3 ranged from 2 to 9%
of cpm bound by 8.1 .6.
C. albicans (JN-CA). Stimulation by 7.13.6 ofa hepatitis B surface antigen-specific
clone, which is restrictedbynon-DR-restricting elements (BJ-HBsAg) is also equivalent
to 8.1.6 levels (Table II). These data indicate that the mutation in 7.13.6 specifically
affects the presentation of PPD to clone ND-PPD1 and does not result in a gener-
alized abnormality of antigen processing or presentation.
The 7.13.6 defect in stimulation of ND-PPDi appears to result from the struc-
tural change in HLA-DR3 molecules rather than the change in the level ofHLA-
DR3 molecules on the cell surface based on the following observations. Doubling
the numberof7.13.6cellsused asAPCdoesnotovercome the defect (data not shown).
In addition, a different 8.1.6-derived DR3p1 structural gene mutant, 7.25.6, which,
like 7.13.6, expresses -50% of8.1.6 levels ofDR3 (see Materials and Methods), stimu-
lates ND-PPD1 at a level equivalent to 8.1.6 (Table II). This indicates that reduc-
tions in HLA-DR3 expression of the magnitude seen in 7.25.6 and 7.13.6 do not
ofthemselves result in reduced stimulation ofND-PPD2 Tcells. These data, as well
as the ability of 7.13.6 to stimulate other DRSI-restricted Tcells normally, suggest
TABLE II
Stimulation of HLA-restricted Antigen-specific T Cells by
Mutants and by 8.1 .6
Data are net antigen-specific cpm from the median of triplicate assays from
a representative experiment. SEM <10% . Relative responses (response to mu-
tant / response to 8.1 .6) were comparable (SEM < 10%) in 2-4 independent
experiments.
* JN-CA is a polyclonal T cell line, specific for C. albicans; as shown, its response
is primarily DR3 restricted when assayed with 8.1 .6 as APC .
[3H]TdR T cell incorporation
APC ND-PPD1 ND-PPD2 CT-TT
cpm x 10 -3
JN-CA* BJ-HBsAg
8.1 .6 25 .5 14.1 5.5 28.2 61 .7
7.13 .6 0 20.4 5.3 30.3 63.4
7.25 .6 24.0 18 .4 ND 34.7 ND
9.4 .3 0 0 0 19.8 ND
9.22.3 0 0 0 2 .6 62.0
6.1 .6 ND ND ND 0 0.4that the functional alteration in mutant 7.13.6 derives from the structural change
in its DR301 chain.
To more precisely identify thestructural basisfor the cell surfaceantibody binding
and functional changes observed in 7.13.6, we determined the site ofthe mutational
lesion in its DROI gene. We used the PCR to amplify the entire DRa and DRO
coding region of cDNAs from 7.13.6 and 8.1.6 and subjected the PCR products to
dideoxy sequence analysis. The DRa gene from 7.13.6 is identical to that of 8.1.6
(data not shown) . However, as shown on Fig. 2, the DRSI gene differs from that
of 8.1.6 by a single base change, a guanine - adenine transition in the first nucleo-
tide ofthe codon for amino acid 9. The mutation changes the encoded residue from
glumatic acid to lysine which is consistent with the two charge basic shift in pI of
the mutant (3t chain observed on 2-D gel analysis. Thus, it appears that a single
amino acid change underlies the functional alterations in the 7.13.6 mutant. The
location of this mutation in the NH2-terminal domain of R chain (the 01 domain)
is not surprising; this domain contains most allelic variant amino acid positions in
the HLA-DR molecule (13), and 7.13.6 was selected for altered reactivity with aDR3-
specific antibody.
The evidence from mutant 7.13.6 implicates the firsthypervariable region (amino
acid positions 9-13) of the (31 domain of the DR(3I chain as important for the stim-
ulation of some DR3-restricted T cells. The third hypervariable region (62-78) is
also involved in presentation ofsoluble antigens (6). Recently, amodel ofthe binding
domain of the class II molecule has been proposed, based on the crystal structure
of HLA class I molecule A2 and on shared features of primary structure of class
I and II molecules (6). In this model, the NH2-terminal portions of the al and (31
domains (including the first hypervariable region) are folded into 0-pleated sheets
and form the bottom of an antigen-binding cleft. The side chains of polymorphic
residues 9, 11, and 13 of the first hypervariable region pointinto theantigen-binding
site. The COOH-terminal portions of the al and 01 domains (including the third
hypervariable region) are a helical structures that form the sides of the cleft. Side
chains of some residues in thehelices point out and are availableforinteraction with
antibodies and TCRs. Position 9, which is altered in 7.13.6, is on thefloorof thecleft
in this model, but its side chain is also in close proximity to the presumed a-helical
portion ofthe DRa chain. This model suggests at least three alternative mechanisms
for the functional alteration in 7.13.6. The glutamic acid at position 9 in normal
DR3 molecules may interact directly with an immunogenic peptide derived from
PPD. Mutations at this site might thereforeinterfere with antigenbinding. Alterna-
tively, the substitution at this site may induce a local conformational change in the
a 9 10
Leu Glu Tyr
8. 1 .6
￿
TTG GAG TAC
7.13.6 --- A-_ ---
Leu Lys Tyr
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FIGURE 2 . The DR3SI nucleotide coding sequence of 7.13.6. The
numbers refer to the amino acid positions. 7.13.6 differs from 8.1.6 by
a G - A transition in codon 9 of the RI chain. Independent evidence
verifying this result was obtained by amplifying and sequencing a seg-
ment of genomic DNA spanning the second exon ofthe DROI genes of
7.13.6 and8.1.6 (datanot shown).The DROI gene of theDRw9 specificity
also has a lysine at position 9, butdiffers from mutant 7.13.6 at positions
10-13 (15).1536 AN AMINO ACID SUBSTITUTION ALTERS ANTIGEN PRESENTATION
a helix of the DRa chain affecting a contact residue for particular TCRs . Thirdly,
the 7.13 .6 mutation in the DR0I chain may perturb its interaction with the NH2-
terminal region of the DRa chain, changing the tertiary structure of the mutant
dimer. These changes might ablate either peptide binding orT cell recognition . Evi-
dence obtained in binding studies of appropriate peptides to purified mutant DR3
molecules from 7 .13.6 should help distinguish among these hypotheses .
Summary
Activation ofT lymphocytes by immunogenic peptides bound toHLA molecules
is a central event in the generation of an immune response. To determine the sites
on HLA molecules involved in this process, we isolated mutant EBVtransformed
B cell clones that express altered HLA-DR3 molecules . One mutant has lost the
ability to stimulate aT cell clone specific for a mycobacterial protein, but retains
the ability to stimulate other antigen-specific T cells . TheDNA sequence ofthe com-
plete DRa and Q coding regions revealed a single nucleotide change resulting in
a glutamic acid to lysine substitution at amino acid 9 in the first hypervariable re-
gion of the DRp chain . These results are discussed in relation to a recently pro-
posed model of class II molecule structure .
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